Saltar al contenido principal
Elsevier

Advances in Prodrugs

Design and Therapeutic Applications

  • 1 Edición - 25 de septiembre de 2024
  • Última edición
  • Editores: Claudiu Trandafir Supuran, Andrea Angeli, Damiano Tanini
  • Idioma: Inglés

Advances in Prodrugs: Design and Therapeutic Applications provides a versatile tool in prodrug design and development as well as a concrete perspective on clinical and preclinical… Leer más

Descripción

Advances in Prodrugs: Design and Therapeutic Applications provides a versatile tool in prodrug design and development as well as a concrete perspective on clinical and preclinical studies currently available on prodrugs. The first part of this book discusses different chemical classes of prodrugs, with particular emphasis on metabolic pathways and mechanisms involved in the activation of their functional groups. The second part of the book covers therapeutic applications of prodrugs against the most discussed diseases, providing detailed discussion on recent achievements in the field. This book offers researchers involved in drug discovery key criteria for the successful development of prodrug-based therapeutic tools.

Prodrugs are inactive drug precursors which undergo different chemical transformation by metabolic processes to provide pharmacologically active compounds. Prodrugs include a broad range of structurally diverse molecules employed for the treatment of several diseases.

Puntos claves

  • Highlights chemistry and pharmacology-related aspects, offering a versatile tool for readers involved in prodrug development and study
  • Discusses in-depth treatment of several activation mechanisms and applications for disease treatments
  • Covers a range of topics from basic contents, design, and mechanisms of actions to current applications in drugs

De interès para

Postgraduate students and researchers working with drug discovery, medicinal chemistry, pharmacology, bioorganic and bioinorganic chemistry

Índice

PART I: INTRODUCTION


1. PRODRUGS: GENERAL CONCEPTS, PRODRUG DESIGN IN MEDICINAL CHEMISTRY
Andrea Angeli, Claudiu T. Supuran and Damiano Tanini

PART II: ACTIVATION MECHANISMS AND RELATED FUNCTIONAL GROUPS

2. pH-SENSITIVE PRODRUGS
Emanuela Berrino

3. ENZYME-MEDIATED ACTIVATION OF PRODRUGS
Simone Carradori, Ilaria D'Agostino and Concettina La Motta

4. REACTIVE OXYGEN SPECIES-RESPONSIVE PRODRUGS
Jean-Yves Winum

5. PHOTOACTIVABLE PRODRUGS
Damiano Tanini

6. ANTIBODY DIRECTED ENZYME PRODRUG THERAPY (ADEPT)
Paolo Rovero, Andrea Di Santo and Anna Maria Papini

7. SELF-ASSEMBLING PRODRUGS
Mariana Pinteala V

8. PRODRUG-BASED NANOMEDICINES: A SUCCESSFUL RATIONALE TO DESIGN NOVEL AND EFFECTIVE DELIVERY STRATEGIES
Giulia Vanti

9. HYPOXIA-ACTIVATED PRODRUGS
Wagdy M. Eldehna

PART III: APPLICATION OF PRODRUGS IN THE TREATMENT OF DISEASES


10. ANTIVIRAL AND ANTIRETROVIRAL PRODRUGS
Claudiu T. Supuran and Luigi Pisano

11. PRODRUGS FOR CANCER THERAPY
Andrea Angeli

12. PRODRUGS FOR NEURODEGENERATIVE DISEASES
Paolo Guglielmi, Arianna Granese, Daniela Secci and Paola Chimenti

13. PRODRUGS IN CARDIOVASCULAR THERAPY
Laura Fumagalli and Angelica Artasensi

14. PRODRUGS FOR OCULAR DISEASES
Alessio Nocentini

15. ANTIBACTERIAL PRODRUGS
Raivis Žalubovskis

16. PRODRUGS AGAINST NEGLECTED DISEASES
ALANE BEATRIZ VERMELHO

Detalles del producto

  • Edición: 1
  • Última edición
  • Publicado: 25 de septiembre de 2024
  • Idioma: Inglés

Sobre los editores

CT

Claudiu Trandafir Supuran

Claudiu T. Supuran received his BSc and PhD in Chemistry from the Polytechnic Univesity of Bucharest (Romania), where he became an Assistant and then Associate Professor of Chemistry. In 1995, he moved to University of Florence, where he is Full Professor. His main research interest focused in medicinal chemistry, design of enzyme modulators especially in the carbonic anhydrase field, X-ray crystallography and molecular biology of metalloenzymes. He has published more than 1900 papers in these fields and his Hirsch index is 155, with > 105 700 citations. One of the compounds discovered in his laboratory (SLC-0111) is in Phase II clinical trials for the treatment of advanced metastatic solid tumors in Canada/USA, whereas a monoclonal antibody of which he is co-discoverer (6A10) is in preclinical evaluation and anti-tumor theragnotic agent. He is the editor-in-Chief of Journal of Enzyme Inhibition and Medicinal Chemistry and of Expert Opinion on Therapeutic Patents.
Afiliaciones y experiencia
University of Florence, NEUROFARBA Department (Italy)

AA

Andrea Angeli

Andrea Angeli obtained his MSc in Medicinal Chemistry and Technologies in 2014 and his PhD in Medicinal Chemistry in 2019 at the University of Florence (Italy). After he spent three years as Assistant researcher at the Centre of Advanced Research in Bionano conjugates and Biopolymers Department, “Petru Poni” Institute of Macromolecular Chemistry (Romania). From 2020 is visiting researcher to University of Florence. His research deals with several aspects of metalloenzymes, spanning from drug design, X-ray crystallography and synthesis of enzyme modulators.
Afiliaciones y experiencia
University of Florence, NEUROFARBA Department Italy

DT

Damiano Tanini

Damiano Tanini received his PhD degree in Chemistry in 2015 from the University of Florence working on the stereoselective synthesis of sulfur- and selenium-containing compounds. He carried out part of his doctoral research at the University of Bristol, working with Prof. V. K. Aggarwal. D. Tanini is currently a researcher in Organic Chemistry at the University of Florence. His research interests currently centre on organic synthesis, ranging from the development of sustainable methodologies towards bioactive molecules to the study of chalcogen-catalysed transformations and molecular chirality. D. Tanini serves as Editorial Board Member of several journals in chemical and biochemical area.
Afiliaciones y experiencia
University of Florence, Department of Chemistry (Italy)

Ver libro en ScienceDirect

Lee Advances in Prodrugs en ScienceDirect